Tris Pharma Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$17.7M
Doctors Paid
24,135
Transactions
132,633
2024 Total
$11.4M
Payment Breakdown by Category
Research$12.3M (69.7%)
Food & Beverage$2.5M (14.3%)
Travel$380,410 (2.2%)
Consulting$194,770 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.3M | 125 | 69.7% |
| Food and Beverage | $2.5M | 129,288 | 14.3% |
| Honoraria | $2.2M | 1,393 | 12.7% |
| Travel and Lodging | $380,410 | 1,697 | 2.2% |
| Consulting Fee | $194,770 | 42 | 1.1% |
| Education | $2,045 | 51 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 0.0% |
| Gift | $820.45 | 36 | 0.0% |
Payments by Type
Research
$12.3M
125 transactions
General
$5.3M
132,508 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TRIPHA TRN-228-301 Abdominoplasty P3_CDIMRSX | $4.9M | 0 | 13 |
| TRIPHA TRN-228-302_Bunion_P3 | $3.3M | 0 | 46 |
| TRIPHA TRN-228-102 Human Abuse Potential P1_CDMPQRSX | $1.4M | 0 | 7 |
| Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD | $1.3M | 0 | 19 |
| A Single Center, Flexible-Dose, 8-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study the Efficacy Of Dyanavel XR In Treating Co-Occurring Fatigue In Adults With Attention Deficit/Hyperactivity Disorder (ADHD) | $543,594 | 1 | 2 |
| A Multiple Dose, Open-Label Study to Evaluate the Safety and Tolerability of a Placebo Formulation of Oxybate Extended-Release Powder for Oral Suspension Administered Once Nightly for 5 Weeks in Healthy Subjects | $431,594 | 0 | 23 |
| Dynavel XR Extended-Release Oral Suspension in the Treatment of Children with ADHD Al Laboratory School Study | $190,146 | 1 | 3 |
| A Retrospective Real World Data Analysis of Hypothesized Causal Relationships of Dyanavel XRs Lower Rate of Supplementation by an Instant-Release Stimulant | $143,450 | 1 | 3 |
| Amphetamine Extended-ReleaseTablets in the Treatment of Adults with ADHD. | $81,897 | 0 | 2 |
| TRI 102-PPK-300 A single dose open label Pharmacokinetic study of Dyanavel XR extended release oral suspension in children 4-5 years with ADHD | $62,096 | 0 | 5 |
| Driving Performance in Patients aged 18 to 25 years with ADHD after a Single-Dose of Amphetamine Extended-Release Tablets: A Double-Blind, Placebo-Controlled Study | $15,000 | 0 | 1 |
| TRI 102-PPK-300 A single dose open label Pharmacokinetic study of Dyanavel XR amphetamine extended release oral suspension in children 4-5 years with ADHD | $11,500 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Joel Young, Md, MD | Psychiatry | Rochester Hills, MI | $710,202 | $0 |
| Dr. Michael Feld, M.d, M.D | Psychiatry | Northbrook, IL | $395,885 | $0 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $255,319 | $0 |
| Unknown Provider | — | — | $217,306 | $0 |
| Dr. Alice Mao, Md, MD | Child & Adolescent Psychiatry | Houston, TX | $197,243 | $0 |
| Dr. Daniel Tan, M.d, M.D | Psychiatry | Houston, TX | $120,090 | $0 |
| Matthew Brams, M.d, M.D | Child & Adolescent Psychiatry | Houston, TX | $94,911 | $0 |
| Dr. Maurice Ohayon, Md, Dsc, Phd, MD, DSC, PHD | Sleep Medicine | Stanford, CA | $90,026 | $0 |
| Susanna Chyu, Do, DO | Psychiatry | Orlando, FL | $78,399 | $0 |
| Dr. Victor Abdow, M.d, M.D | Pediatrics | Rockville, MD | $76,383 | $0 |
| Dr. Lionel Tridas, M.d, M.D | Developmental - Behavioral Pediatrics | Tampa, FL | $76,154 | $0 |
| Unknown Provider | — | — | $65,442 | $0 |
| Luis Escobar, Md, MD | Anesthesiology | Indianapolis, IN | $64,145 | $0 |
| Dr. Birgit Amann, M.d, M.D | Child & Adolescent Psychiatry | Troy, MI | $57,104 | $0 |
| Cathal Grant, M.d, M.D | Psychiatry | Bedford, TX | $46,914 | $0 |
| Mark Wright, M.d, M.D | Psychiatry | Lexington, KY | $46,847 | $0 |
| Dr. James Wiley, M.d, M.D | Pediatrics | Mobile, AL | $46,278 | $0 |
| Dr. Shabana Jessani, M.d, M.D | Developmental - Behavioral Pediatrics | Chandler, AZ | $44,458 | $0 |
| Mr. Sunil Kottur, Md, MD | Child & Adolescent Psychiatry | Plano, TX | $41,721 | $0 |
| Dr. Terry Dickson, M.d, M.D | Developmental - Behavioral Pediatrics | Traverse City, MI | $40,432 | $0 |
| Dr. Brian Barash, M.d, M.D | Psychiatry | Kansas City, MO | $40,332 | $0 |
| Dr. Edmund Williams, Md, MD | Child & Adolescent Psychiatry | San Antonio, TX | $38,844 | $0 |
| Sricharan Moturi, Md, MD | Psychiatry | Franklin, TN | $38,843 | $0 |
| Mr. Greg Rosenn, Md, MD | Neurology with Special Qualifications in Child Neurology | Plainview, NY | $38,742 | $0 |
| Andrew Cutler, Md, MD | Internal Medicine | Watertown, MA | $34,759 | $0 |
Ad
Top Products
- Dyanavel XR $5.0M
- Dyanavel XR extended-release tablets $1.4M
Associated Products (6)
- Dyanavel XR $5.0M
- Dyanavel XR extended-release tablets $1.4M
- Quillichew ER $484,627
- Quillivant $302,891
- Quillivant XR $251,534
- Onyda XR $15,957
Payment Categories
- Food & Beverage $2.5M
- Consulting $194,770
- Travel & Lodging $380,410
- Research $12.3M
About Tris Pharma Inc
Tris Pharma Inc has made $17.7M in payments to 24,135 healthcare providers, recorded across 132,633 transactions in the CMS Open Payments database. In 2024, the company paid $11.4M. The top product by payment volume is Dyanavel XR ($5.0M).
Payments were distributed across 202 medical specialties. The top specialty by payment amount is Psychiatry ($2.1M to 2,614 doctors).
Payment categories include: Food & Beverage ($2.5M), Consulting ($194,770), Research ($12.3M), Travel & Lodging ($380,410).
Tris Pharma Inc is associated with 6 products in the CMS Open Payments database, including Dyanavel XR, Dyanavel XR extended-release tablets, and Quillichew ER.